BACKGROUND Antiplatelet antibodies are detected in multiple diseases including primary immune thrombocytopenia (ITP). Dynamics of how these antibodies change over time in ITP is unknown in dogs. HYPOTHESIS/OBJECTIVES Antiplatelet antibodies (APA) will be detected in thrombocytopenic dogs with multiple etiologies and dynamics of APA in dogs with ITP can be used to evaluate response to treatment and relapse. Determine APA at the time of diagnosis in thrombocytopenic dogs and serially in primary ITP dogs. ANIMALS Seventy-nine thrombocytopenic dogs and 28 primary ITP dogs. METHODS Direct flow cytometry was performed in thrombocytopenic dogs at initial evaluation and serially in suspected primary ITP dogs. In primary ITP dogs, a 2-tailed Fisher's exact test was performed comparing survival to discharge between dogs with and without melena and to relate response to treatment and relapse to changes in APA and platelet count (repeated measures analysis, Spearman correlation). RESULTS Twenty percent (16/79) of thrombocytopenic non-ITP dogs with infectious, neoplastic, or other diseases and all primary ITP dogs were positive for APA. Melena at initial evaluation was associated with decreased survival to discharge (odds ratio 0.06; P = .01). Persistence of APA was not associated with response to treatment, but recurrence of antibodies was associated with relapse (odds ratio 205.0; P < .01). There was no difference in percentage of APA or platelet count at initial diagnosis between dogs that did or did not respond to treatment. CONCLUSIONS AND CLINICAL IMPORTANCE Serial monitoring of APA in dogs with primary ITP appeared beneficial for determining relapse of disease.

中文翻译：

---

有和没有特发性免疫性血小板减少症的血小板减少症狗中抗血小板抗体的检测和动力学。

背景技术在包括原发性免疫性血小板减少症（ITP）在内的多种疾病中检测到抗血小板抗体。这些抗体在ITP中如何随时间变化的动力学在犬中尚不清楚。假设/目的将在具有多种病因的血小板减少症犬中检测到抗血小板抗体（APA），ITP犬中APA的动力学可用于评估对治疗和复发的反应。在血小板减少犬和原发性ITP犬诊断时确定APA。动物79只血小板减少症犬和28只原发性ITP犬。方法最初评估时对血小板减少症犬进行直接流式细胞术，对疑似原发性ITP犬进行连续流式细胞术。在初级ITP犬中，有2尾Fisher' 进行了准确的测试，比较了有黑斑狗和无黑斑狗之间的存活率和出院率，并将治疗反应和复发与APA和血小板计数的变化相关联（重复测量分析，Spearman相关性）。结果患有传染性，肿瘤性或其他疾病的血小板减少性非ITP犬和所有原发性ITP犬中有20％（16/79）的APA阳性。初次评估时，梅勒娜（Melena）与出院存活率下降相关（赔率比为0.06； P = 0.01）。APA的持久性与治疗反应无​​关，但抗体的复发与复发相关（优势比205.0； P <.01）。在最初诊断时，对治疗有反应或没有反应的狗之间的APA或血小板计数百分比没有差异。